2025
Experimental Swine Models for Vascularized Composite Allotransplantation and Immunosuppression: A Systematic Review and Case Report of a Novel Heterotopic Hemifacial Swine Model
Knoedler L, Klimitz F, Huelsboemer L, Niederegger T, Schaschinger T, Knoedler S, Boroumand S, Brown S, Pomahac B, Kauke-Navarro M. Experimental Swine Models for Vascularized Composite Allotransplantation and Immunosuppression: A Systematic Review and Case Report of a Novel Heterotopic Hemifacial Swine Model. Transplant International 2025, 38: 14520. PMID: 40799314, PMCID: PMC12341719, DOI: 10.3389/ti.2025.14520.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationImmunosuppressive strategiesImmunological environmentCase reportVCA modelFacial Vascularized Composite AllotransplantationSwine modelSystematic reviewMGH miniature swineMiniature swineHemiface transplantationsSerial skinImmunosuppressive regimensOral functionOrthotopic modelLifelong immunosuppressionTransplantation modelLocal drug deliveryMucosal biopsiesExperimental swine modelVascular experienceExperimental therapiesFacial allograftHeterotopic modelImmune mechanismsSkin Elasticity: A Potential Surrogate Marker for Facial Allograft Skin Fibrosis—A Case Series
Stögner V, Boroumand S, Vafa A, Huelsboemer L, Kauke‐Navarro M, Formica R, Leffell D, Haykal S, Pomahac B. Skin Elasticity: A Potential Surrogate Marker for Facial Allograft Skin Fibrosis—A Case Series. Clinical Transplantation 2025, 39: e70175. PMID: 40460163, DOI: 10.1111/ctr.70175.Peer-Reviewed Original ResearchConceptsPost-transplant yearVascularized Composite AllotransplantationRecipient/donor ageImmunosuppressive regimensSurrogate markerSmoking statusVascularized composite allotransplantation recipientsPotential surrogate markersBilateral upper armsFace transplant recipientsSkin elasticity measurementsAllograft fibrosisChronic rejectionGraft lossTransplant recipientsBilateral cheeksCase seriesDermal fibrosisSkin changesFacial allograftDegenerative skin changesGraft changesFacial skinNet elasticityRejection burden
2024
Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchConceptsRegulatory myeloid cellsSolid organ transplantationVascularized Composite AllotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejectionImmunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes
Huelsboemer L, Boroumand S, Kochen A, Dony A, Moscarelli J, Hauc S, Stögner V, Formica R, Pomahac B, Kauke-Navarro M. Immunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes. Frontiers In Transplantation 2024, 3: 1366243. PMID: 38993787, PMCID: PMC11235358, DOI: 10.3389/frtra.2024.1366243.Peer-Reviewed Original ResearchCMV infectionImmunosuppressive regimensImmunosuppressive strategiesTransplant recipientsIncidence of rejection episodesClinical CMV infectionTriple maintenance therapyIncidence of rejectionEpisodes of rejectionIndividualized immunosuppressive regimensEffective immunosuppressive therapySystematic reviewFace transplant patientsHand transplant recipientsHand transplantationFacial graftImmunosuppressive therapyMaintenance therapyRejection episodesFacial mucosaGraft lossGraft rejectionTherapy regimensTransplant patientsRenal failure
2023
Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation
Kauke-Navarro M, Noel O, Knoedler L, Knoedler S, Panayi A, Stoegner V, Huelsboemer L, Pomahac B. Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation. Journal Of Surgical Research 2023, 291: 176-186. PMID: 37429217, DOI: 10.1016/j.jss.2023.04.028.Peer-Reviewed Original ResearchConceptsImmunosuppressive regimensAllograft rejectionComposite allotransplantationDonor-derived immune cellsDonor-derived T lymphocytesRecipient-derived T cellsPotent immunosuppressive regimensToxic immunosuppressive regimensSolid organ transplantationAntigen-presenting cellsSystemic side effectsVascularized Composite AllotransplantationCD40 knockoutChronic rejectionRejection episodesSystemic immunosuppressionMost patientsImmunomodulatory strategiesTolerance inductionImmune cellsOrgan transplantationT cellsT lymphocytesSide effectsClinical success
2021
A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models
Kauke M, Safi AF, Panayi AC, Palmer WJ, Haug V, Kollar B, Nelms L, Tchiloemba B, Pomahac B. A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models. Journal Of Plastic Reconstructive & Aesthetic Surgery 2021, 75: 586-604. PMID: 34895853, DOI: 10.1016/j.bjps.2021.11.003.Peer-Reviewed Original ResearchConceptsSystematic reviewImmunomodulatory strategiesPreclinical researchAvailable immunosuppressive regimensCurrent standard regimenSystemic side effectsDrug-based approachesMeta-Analyses (PRISMA) guidelinesVCA modelPreferred Reporting ItemsHind limb modelNovel immunomodulatoryRejection episodesAcute rejectionImmunosuppressive regimensStandard regimenAllograft acceptanceAlloimmune responseSuppression therapyImmunomodulation strategiesLimb transplantsPreclinical modelsRat modelHuman trialsTherapeutic approaches
2019
Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Stahl M, Bewersdorf J, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica 2019, 105: 102-111. PMID: 31004015, PMCID: PMC6939518, DOI: 10.3324/haematol.2019.219345.Peer-Reviewed Original ResearchConceptsImmunosuppressive therapyProspective cohort studyMyelodysplastic syndromeClinical trialsResponse rateCohort studySystematic reviewLower-risk myelodysplastic syndromesLow-risk MDS patientsDifferent immunosuppressive regimensTransfusion independence rateAnti-thymocyte globulinComplete remission rateRelevant conference proceedingsOverall response rateTreatment of patientsAcute myeloid leukemiaHigh-quality studiesHigh response rateRandom-effects modelWeb of ScienceImmunosuppressive regimensPatient yearsRemission rateAdverse eventsNovel immunological and clinical insights in vascularized composite allotransplantation
Kollar B, Pomahac B, Riella L. Novel immunological and clinical insights in vascularized composite allotransplantation. Current Opinion In Organ Transplantation 2019, 24: 42-48. PMID: 30531538, DOI: 10.1097/mot.0000000000000592.Peer-Reviewed Original ResearchConceptsAcute rejectionT cellsComposite allotransplantationField of VCANovel immunosuppressive approachAntibody-mediated rejectionCurrent histological classificationNovel noninvasive biomarkersQuality of lifeType of rejectionIntensity of treatmentFace transplant recipientsChronic rejectionImmunosuppressive regimensVCA patientsVCA recipientsAllograft injuryCostimulation blockadeImmunosuppressive approachesImmunosuppressive therapyTransplant recipientsImmune monitoringUpper extremityHistological classificationVCA outcomes
2018
Transgenic Expression of hCD47 Minimizes the Development of Proteinuria Following Pig-to-Baboon Kidney Transplantation and Reduces Phagocytosis of Porcine Endothelial Cells and Podocytes
Nomura S, Watanabe H, Ariyoshi Y, Pomposelli T, Garcia G, Sekijima M, Boyd L, Ekanayake-Alper D, Glor H, Tanabe T, Arn S, Hawley R, Sykes M, Sachs D, Richard J, Yamada K. Transgenic Expression of hCD47 Minimizes the Development of Proteinuria Following Pig-to-Baboon Kidney Transplantation and Reduces Phagocytosis of Porcine Endothelial Cells and Podocytes. Transplantation 2018, 102: s314-s315. DOI: 10.1097/01.tp.0000543036.39314.a6.Peer-Reviewed Original ResearchDevelopment of proteinuriaPorcine endothelial cellsEndothelial cellsGroup 2Development of massive proteinuriaGroup 1Glomerular cellsGlomerular endothelial damageExpression of hCD55Statistically significant reductionCo-culture assayIn vitro studiesCTLA-4IgImmunosuppressive regimensMinimal proteinuriaCTLA4-IgKidney transplantationMassive proteinuriaReduction of phagocytosisEndothelial damageInflammatory cascadeMediated cytotoxicityProteinuriaPromoting proteinuriaGroup 3The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013
Tsai DE, Bagley S, Reshef R, Shaked A, Bloom RD, Ahya V, Goldberg L, Chung A, Debonera F, Schuster SJ, Huntington SF. The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. American Journal Of Hematology 2018, 93: 874-881. PMID: 29659047, DOI: 10.1002/ajh.25116.Peer-Reviewed Original ResearchConceptsPosttransplant lymphoproliferative disorderEBV serostatusMonomorphic histologyPTLD casesLymphoproliferative disordersMonomorphic posttransplant lymphoproliferative disorderPolymorphic posttransplant lymphoproliferative disordersTime of transplantTacrolimus useImmunosuppressive regimensImmunosuppressive therapyTransplant patientsTransplant recipientsClinical managementDifferent prognosisOPTN databaseOrgan transplantationDifferent malignanciesHistologyLate occurrenceSerostatusTransplantPotential causesTherapyDisorders
2017
Epidemiology of Bloodstream Infections
McMullen A, Wilen C, Burnham C. Epidemiology of Bloodstream Infections. 2017, 163-181. DOI: 10.1128/9781555819811.ch9.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSolid organ transplantationBloodstream infectionsStem cell transplantationPositive blood culturesHealth care settingsImmunosuppressive regimensClinical microbiology laboratoryCell transplantationBlood culturesOrgan transplantationCare settingsInvasive proceduresPractice changeMicrobiology laboratoryEpidemiologyInfectionAntimicrobial resistanceHealth careTransplantationNumber of advancesRegimensSettingCare
2016
Liver Transplantation: An Overview
Kim J, Hong J. Liver Transplantation: An Overview. 2016, 599-619. DOI: 10.1007/978-3-319-30103-7_36.Peer-Reviewed Original ResearchOrthotopic liver transplantationLiver transplantationGraft failurePrimary nonfunctionRecurrence of primary liver diseaseAbsence of systemic metastasisOrthotopic liver transplant recipientsPatient’s MELD scorePractice of liver transplantationDeceased donor liver graftsIrreversible liver failureBile duct cancerPrimary liver diseaseLiver transplant waiting listPatient survival outcomesDonor liver graftsWaiting listHepatic allograft functionTransplant waiting listImmunosuppressive regimensSystemic metastasesAllograft functionChronic rejectionLife-saving treatmentSurvival outcomesDe Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient
Cohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsHuman immunodeficiency virus–positive kidney transplant recipientHIV-positive renal transplant recipientsPositive renal transplant recipientsHIV-positive Black menActive antiretroviral agentsKidney transplant recipientsNew-onset diabetesHuman immunodeficiency virusImmunosuppressive regimensFirst transplantAntiretroviral agentsCalcineurin inhibitorsImmunodeficiency virusKidney donorsDrug interactionsTransplantRecipientsBlack menSuccessful casesDe novoBelataceptHypertensionHyperlipidemia
2014
Fortschritte in der Gesichtstransplantation
Kueckelhaus M, Lehnhardt M, Fischer S, Eriksson E, Pomahac B, Hirsch T. Fortschritte in der Gesichtstransplantation. Handchirurgie · Mikrochirurgie · Plastische Chirurgie 2014, 46: 206-213. PMID: 25162238, DOI: 10.1055/s-0034-1385850.Peer-Reviewed Original ResearchConceptsVascularised composite allotransplantationFace transplantationLife-threatening side effectsSolid organ transplantationDifferent transplant centersImmunosuppressive regimensMaintenance immunosuppressionVCA proceduresImmunosuppressive strategiesTransplant centersPatients' qualityLifelong immunosuppressionOrgan preservationSurgical techniqueOrgan transplantationComposite allograftsComposite allotransplantationSide effectsTransplantationFunctional reintegrationImmunosuppressionAnatomic structuresImmunogenic partFirst caseDifferent protocols
2003
Recent Advances in Liver Transplantation
Wiesner RH, Rakela J, Ishitani MB, Mulligan DC, Spivey JR, Steers JL, Krom RA. Recent Advances in Liver Transplantation. Mayo Clinic Proceedings 2003, 78: 197-210. PMID: 12583530, DOI: 10.4065/78.2.197.Peer-Reviewed Original ResearchConceptsLiver transplantationHepatitis CEnd-stage liver disease (MELD) allocation systemRecurrent hepatitis C.Acute cellular rejectionDonor liver transplantationRecurrent hepatitis CDeath of patientsLong-term survivalLiver allocation policyQuality of lifeCellular rejectionChronic rejectionDomino transplantationImmunosuppressive regimensMetabolic complicationsRecurrent diseaseHepatitis C.Marginal donorsProlong survivalUnited NetworkHepatic support systemDonor poolEffective therapyDonor organs
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply